

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 August 2002 (29.08.2002)


PCT

(10) International Publication Number  
**WO 02/066978 A2**

- (51) International Patent Classification<sup>7</sup>: **G01N 33/50**, 33/68, A61P 29/00 30092 (US). CAHOON, Shianlen [US/US]; 425 Windy Ridge Lane, Atlanta, GA 30339 (US).
- (21) International Application Number: PCT/US01/50818 (74) Agents: PRATT, John, S. et al.; Kilpatrick Stockton LLP, Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309-4530 (US).
- (22) International Filing Date: 21 December 2001 (21.12.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/259,306 29 December 2000 (29.12.2000) US
- (71) Applicants (for all designated States except US): REDDY US THERAPEUTICS, INC. [US/US]; 3065 Northwoods Circle, Norcross, GA 30071-1542 (US). SAXENA, Uday [IN/US]; 2900 Galahad Drive, Atlanta, GA 30345 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): PILLARISETTI, Sivaram [IN/US]; 4762 Grand Heron Court, Norcross, GA
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHODS AND COMPOSITIONS FOR DETECTING COMPOUNDS THAT MODULATE INFLAMMATORY RESPONSES



(57) Abstract: The present invention relates to compositions and methods for identification and development of compounds or therapeutic agents that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to methods for detecting compounds or therapeutic agents that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in cells. The present invention provides compositions for and methods of treatment of biological conditions including, but not limited to, vascular complications of type I and type II diabetic induced vasculopathies, other vasculopathies, microangiopathies, renal insufficiency, Alzheimer's syndrome, and inflammation-induced diseases such as atherosclerosis.



WO 02/066978 A2



**Published:**

— without international search report and to be republished  
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

5

## **Methods and Compositions for Detecting Compounds that Modulate Inflammatory Responses**

10

### **Technical Field**

15

The present invention relates to compositions and methods for identifying compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to methods and compositions for treating inflammation and inflammation related diseases, and preferably comprise compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells.

20

### **Background of the Invention**

25

30

Glycated proteins and advanced glycation end products (AGE) accumulate slowly in vascular and renal tissues with age, and more rapidly in inflammatory disease states. AGE contribute to cellular damage, particularly, diabetic tissue injury, by at least two major mechanisms: modulation of cellular functions through interactions with specific cell surface receptors, and alteration of the extracellular matrix leading to the formation of protein cross-links. Studies suggest that glycated protein and AGE interactions with cells may promote inflammatory processes and oxidative cellular injury. Diseases where glycated protein and AGE accumulation is a suspected etiological factor include vascular complications of diabetes, ventricular hypertrophy, atherosclerosis, angiopathy,

myocarditis, nephritis, arthritis, glomerulonephritis, microangiopathies, renal insufficiency and Alzheimer's disease.

5 The exact mechanisms by which high plasma glucose, as seen in diabetes, causes microvascular damage are not completely understood. One potential mechanism by which hyperglycemia can be linked to microangiopathies is through the process of non-enzymatic glycation of critical proteins (1-3). Non-enzymatic glycation, i.e. the linking of proteins with glucose, leads to the formation of glycated proteins. The first  
10 step in this glycation pathway involves the non-enzymatic condensation of glucose with free amino groups in the protein, primarily the epsilon-amino groups of lysine residues, forming the Amadori adducts. These early glycation products can undergo further reactions such as rearrangements, dehydration and condensations to form irreversible advanced glycation end  
15 products (AGE). AGE are a highly reactive group of molecules whose interaction with specific cell-surface receptors, are thought to lead to pathogenic outcomes. Accumulation of glycated proteins is found in the basement membrane of patients with diabetes and is thought to be involved in the development  
20 of diabetic nephropathy and retinopathy (4,5). Inhibitors of AGE formation, such as aminoguanidine, prevent development of diabetes complications, including diabetic retinopathy (6-8).

25 The best characterized AGE receptor is RAGE, receptor for AGE (3). Several in vitro and in vivo studies have shown that blocking RAGE either by antibodies or by adding a soluble form of the receptor inhibits diabetic vasculopathy including diabetic atherosclerosis (9-11). Apart from AGE, RAGE appears to mediate the binding of several other ligands that are  
30 involved in normal physiology as well as pathology (12,13). Thus, merely blocking RAGE might have other unintended consequences. Moreover, since blocking RAGE would lead to accumulation of AGE in circulation, the long-term effects of blocking RAGE are unknown and may be more harmful than  
35 the pathology sought to be prevented.

There are currently no efficient methods for determining compounds effective for the inhibition of AGE or glycated protein accumulation. What is needed are methods and compositions for detecting compounds that can be used to interfere with the production of glycated proteins or AGE. Such detection methods and compositions need to be high throughput and capable of determining effective compounds easily.

### Summary of the Invention

The present invention is directed to methods and compositions for the detection of compounds that are effective in the inhibition of AGE and glycated protein inflammation. The methods of the present invention comprise addition of compounds to assays that measure inflammation created by AGE or glycated protein accumulation and determination of the effect of the compounds, such as inhibition of inflammation by the compounds. Such assays are rapid and accurate tests for glycated protein-induced inflammation and the inhibition of such inflammation by potential therapeutic compounds.

Preferred embodiments of the present invention include methods and compositions for the measurement of endothelial cytokines induced by glycated protein-induced inflammation. More preferred assays measure determinants such as, but not limited to, NF- $\kappa$ B, IL-1 $\beta$  (interleukin 1 $\beta$ ), IL-11 (interleukin 11), m-CSF (macrophage colony stimulating factor), fibrinogen, TNF- $\alpha$  (tumor necrosis factor  $\alpha$ ), adhesion molecules, selectins, VCAM-1 (Vascular Cell Adhesion Molecule-1), CRP (C-reactive protein), and PAI-1 (plasminogen activator inhibitor-1). Most preferred cytokines include IL-6 and monocyte chemoattractant protein 1 (MCP-1). These assays provide for rapid and accurate high throughput screening of molecules that block or inhibit glycated protein-induced inflammation. The identification of these effector molecules and compounds leads to effective therapies for treatment of pathologies resulting from

the biological effects of AGE and glycated protein accumulations and interactions.

5 The present invention also comprises compositions comprising the compounds identified by the assays as having a desired activity. The compositions have utility in treatment of cells, tissues or whole organisms. Such compositions are formulated for administration in an effective amount for treatment of conditions such as biological conditions including, but not limited to, vascular complications of type I and type II  
10 diabetic induced vasculopathies, other vasculopathies, microangiopathies, renal insufficiency, Alzheimer's syndrome, and inflammation-induced diseases including, but not limited to, atherosclerosis. The compositions may comprise pharmaceutical adjuncts that are needed for administration of the compound or  
15 compounds with the desired activity.

#### **Brief Description of the Figures**

Figure 1 is a graph showing the effects of glycated human serum albumin (G-HSA) in induction of IL-6 production in  
20 endothelial cells.

Figure 2 is a graph showing the effects of G-HSA in induction MCP-1 production in endothelial cells.

Figure 3 is a graph showing results obtained from screening a collection of compounds to identify those  
25 compounds that block G-HSA produced induction of IL-6 in endothelial cells.

### Detailed Description of the Invention

The present invention is directed to methods and compositions for detecting compounds or molecules that have specific biological effects and that may be useful as therapeutic agents. In particular, the present invention is directed to methods and compositions for detecting compounds or molecules that effect inflammation. More particularly, the present invention is directed to methods and compositions for detecting compounds or molecules that are effective in inhibiting inflammation caused by the accumulation or presence of glycated proteins or AGE. The present invention also provides compositions for and methods of treatment for biological conditions including, but not limited to, vascular complications of type I and type II diabetic-induced vasculopathies, other vasculopathies, angiopathy, myocarditis, nephritis, arthritis, coronary artery disease, microangiopathies, renal insufficiency, Alzheimer's syndrome, and inflammation-induced diseases including, but not limited to, atherosclerosis.

The present invention is useful in determining which compounds or molecules are active in inhibiting inflammation or cell activation by glycated proteins or AGE. AGE increases lipoprotein oxidizability and atherogenicity. Not wishing to be bound by any particular theory, it is thought that AGE binds to matrix proteins, induces synthesis of IL-1, TNF $\alpha$ , VCAM-1, Heme oxygenase, insulin like growth factor and IL-6, and activates NF- $\kappa$ B. Pharmacological inhibition of AGE-induced cell activation may provide the basis for therapeutic intervention in many diseases, most notably in diabetic complications and Alzheimer's disease. Therapeutic approaches for inhibition of AGE-induced inflammation include, but are not limited to, blocking the glycation of proteins, blocking AGE interactions with receptors and blocking AGE-induced signaling or signaling-associated inflammatory responses.

Useful methods to block AGE effects are determining inhibitors that block AGE induced signaling. The sequence of

5 signaling events leading to inflammation are unclear. A way to overcome this problem is to screen for compounds that block AGE-induced up-regulation of inflammatory molecules. The present invention comprises methods and compositions that enable one to screen for such compounds or molecules.

10 Preferred embodiments of the present invention comprise methods for screening for compounds that block glycated protein-induced inflammation. More preferred embodiments comprise methods for screening for inhibitory compounds or molecules that comprise addition of such compounds to assays for measuring inflammatory determinants, such as inflammatory cytokines, and determining the inhibitory effects of the compound. Most preferred embodiments comprise methods comprising assays wherein glycated albumin stimulates  
15 endothelial production of determinants, particularly determinants of inflammation such as IL-6, MCP-1, IL1- $\beta$ , TNF- $\alpha$ , CRP, PAI-1, VCAM-1, ICAM-1, selectins, and adhesion molecules. The endothelial cell is important in inflammation reactions, and the methods and compositions described herein provide for high throughput screening of  
20 molecules that block glycated protein-induced inflammation.

25 As used herein, the term "compound" includes both the singular and the plural, and includes any single entity or combined entities that have activity that can be measured in the assays of the present invention. Such entities include, but are not limited to, chemical elements, molecules, compounds, mixtures, emulsions, chemotherapeutic agents, pharmacological agents, hormones, antibodies, growth factors, cellular factors, nucleic acids, proteins, peptides, peptidomimetics, nucleotides,  
30 carbohydrates, and combinations, fragments, analogs or derivatives of such entities.

35 In the assays of the present invention, the compound initially has unknown activity, effect or effects. The activity of the compound is unknown, in that the compound's effects in the assays of the present invention are not yet determined. The

compound may have many other known activities, and may be a compound that has other therapeutic uses.

5 Stimulatory agent, as used herein, is the component of the assay that stimulates the cells of the assay to respond in a predetermined or known manner. The stimulatory agent can be a chemical compound or molecule or a biological factor. In a most preferred embodiment, the stimulatory agent is a glycated protein, most preferably, glycated human serum albumin (G-HSA). Glycated protein, as used herein, includes proteins  
10 linked to glucose, either enzymatically or non-enzymatically, primarily by condensation of free epsilon-amino groups in the protein with glucose, forming Amadori adducts. Furthermore, glycated protein, as used herein, includes not only proteins containing these initial glycation products, but also glycation products resulting from further reactions such as rearrangements, dehydration, and condensations that form irreversible advanced glycation end products. This embodiment is not limiting and any agent that causes the cells or components of the assay to respond in a measurable manner is contemplated  
15 by the present invention.

Enhanced formation and accumulation of glycated proteins and AGE are thought to play a major role in the pathogenesis of diabetic complications, and atherosclerosis, leading to the development of a range of diabetic complications  
25 including nephropathy, retinopathy and neuropathy (1-3). There is ample *in vivo* evidence that suggests that diabetes-related complications can be reduced by 1) preventing glycation of proteins (6-8) 2) by breaking the cross-links in glycated proteins (22) or 3) by blocking glycated protein interaction with  
30 receptors (10,11). Despite the importance of AGE in the pathogenesis of diabetic microangiopathies, and vasculopathies, there are no currently available medications known to block AGE formation.

Aminoguanidine, which prevents AGE formation, is  
35 actively pursued as a therapy for diabetic vasculopathy (8-10).

However it is not clear whether this drug would affect normal glucose metabolism or glycosylation of proteins. Moreover, some studies show that although aminoguanidine reduces AGE formation, it did not inhibit glomerular basement thickness in diabetic rats nor improved endothelial function (18,19).

In addition to the AGE formation inhibitors, AGE cross-link breakers are also actively pursued as a therapy for vasculopathy. N-Phenacylthiazolium bromide (PTB) is a prototype AGE cross-link breaker that reacts with and cleaves covalent AGE-derived protein cross-links. Although PTB reduced AGE accumulation, it did not prevent vascular permeability.

Inhibition of reactions with receptors of AGE are an alternative approach to treatment of related pathologies. RAGE, a known receptor for AGE, is a possible therapeutic target. Blocking RAGE also inhibited AGE-induced inflammation. However, because of the multiple functions of RAGE and possible long term side effects of accumulated AGE in plasma, this method is not currently pursued in humans. Using the methods and compositions of the present invention, more specific inhibitory compounds can be determined.

Though not wishing to be bound by any particular theory, it is theorized that the present invention utilizes the end point measurement in AGE-induced inflammation. Endothelium is the target organ of damage in diabetes (20,21). Up-regulation of molecules involved in endothelial inflammation, such as IL-6 and monocyte chemoattractant protein-1 (MCP-1) leads to endothelial dysfunction and vasculopathy (21). An overall approach to the understanding and treatment of diabetes and its complications is to interfere in the regulation of genes, such as these two.

The present invention comprises methods and compositions for measuring the activity of compounds. Such methods comprise assays for specific activity of biological components involved in a known cellular response. The assays

provide a measurable response in which the activity of the compounds is determined. This response can be measured by methods known to those skilled in the art, preferably in an ELISA. A preferred embodiment of the present invention comprises measurement of the effects of compounds on an inflammatory response by cells to the presence of a stimulating agent.

In another embodiment of the present invention, a composition suspected of effecting inflammation is added to cells which are then treated with a stimulatory agent. The stimulatory agent may also be added prior to or simultaneously with the composition suspected of effecting inflammation. The cells respond by producing specific determinants of inflammation. The amount of these determinants can be measured by methods known to those skilled in the art and compared to the amount of determinants produced by cells which are treated with the stimulating agent and not the composition suspected of effecting inflammation. The compound may have a stimulating effect, an inhibitory effect, a stabilizing effect, or no effect at all.

A further embodiment of the present invention comprises an assay comprising endothelial cells that are stimulated by the addition of a glycated protein, the stimulating agent. The endothelial cells respond by producing specific cytokines. The amount of cytokines produced are determined by measurement protocols known to those skilled in the art. Compounds having unknown effects are added to the same assay conditions and the production of cytokines is measured. From the comparison of the assay without the compound with the assay with the compound, the biological effect of the compound can be determined. The compound may have an inhibitory effect, a stimulatory effect, a stabilizing effect or no effect at all.

Another preferred embodiment of the present invention comprises measurement of the effects of compounds on the

accumulation of AGE or glycated proteins by measuring the response of cells.

5 In another embodiment of the present invention, a composition suspected of effecting the accumulation of AGE or glycated protein is added to cells which are also treated with a glycated protein. The glycated protein can be added prior to, subsequently to or simultaneously with the composition suspected of effecting accumulation of AGE or glycated protein. The cells respond by producing specific determinants of AGE or glycated protein accumulation. The amount of these determinants can be measured by methods known to those skilled in the art and compared to the amount of determinants produced by cells which are treated with the stimulating agent and not the composition suspected of effecting AGE or glycated protein accumulation. The compound may have a stimulating effect, an inhibitory effect, a stabilizing effect, or no effect at all.

20 Most preferred embodiments of the present invention comprise methods for determining the activity of compounds using assays. The preferred assays comprise endothelial cells that are stimulated in an inflammatory response by the presence of the glycated protein, glycated human serum albumin. The endothelial cells of the preferred embodiment produce cytokines. A preferred method comprises measurement of the amount of the cytokine IL-6 and another preferred embodiment comprises measurement of the amount of the cytokine MCP-1. Preferably, the amount of cytokine produced is determined using immunological methods, more preferably using ELISA assays. The methods of the present invention are not limited by the type of assay used to measure the amount of cytokine produced, and any methods known to those skilled in the art and later developed can be used to measure the amount of cytokines produced in response to the stimulating agent and to the compound having unknown activity.

IL-6 is a pro-inflammatory cytokine that is known to play a key role in the pathogenesis of diabetes and atherosclerosis (23). IL-6 also promotes the growth of renal mesangial cells thus contributing to nephropathy (24). The serum IL-6 level in diabetic subjects was significantly higher than in normal healthy controls (3.48 +/- 3.29 pg/ml vs 0.784 +/- 0.90 pg/ml, mean +/- SD). In addition the urinary IL-6 level is a good indicator of diabetic nephropathy. Serum IL-6 is useful in the evaluation of atherosclerosis and nephropathy.

MCP-1, another pro-inflammatory cytokine is found highly expressed in human atherosclerotic lesions and postulated to play a central role in monocyte recruitment into the arterial wall and developing lesions. Recent results show that MCP-1 is also a key pathogenic molecule in diabetic nephropathy (25). The levels of urinary MCP-1 in patients with the advanced stage were significantly higher than those in patients with the mild stage of the disease, or in healthy controls. The measurement of urinary MCP-1 is useful in evaluating the degree of renal injuries and/or prognosis in patients with nephropathy.

Glycated albumin stimulates endothelial production of IL-6 and MCP-1. The effects on IL-6 are comparable to that of TNF $\alpha$ , a known inducer of IL-6. Because of the well established role of these cytokines in vascular diseases, screening for compounds that block AGE-induction of these cytokines provides a novel approach for identifying therapeutic agents that block AGE-induced inflammation *in vivo*.

In a preferred embodiment, once the baseline response to the stimulating agent for the production of cytokines by the endothelial cells is established, thus comprising the control levels for the screening assay, the methods comprise addition of compounds having unknown activities. The effect of the compound on the baseline response is determined by comparing the amount of cytokine produced in the presence of the stimulating agent and the amount of cytokine produced in the

presence of the stimulating agent and the compound having unknown activity. In a preferred method, compounds that have inhibitory effects on the inflammation of the cells in the presence of G-HSA are then selected for further testing for use as therapeutic agents. One or more compounds may be added to the screening assay. Combinations or mixtures of compounds can be added. Different amounts and formulations of the compounds are added to determine the effects on the screening assay. The screening assay may also be used to determine stimulatory compounds or compounds that have no effects in the assay.

The present invention also comprises compositions comprising the compounds identified by the methods as having a desired activity. The compositions have utility in treatment of cells, tissues or whole organisms. Such compositions are formulated for administration in an effective amount for treatment of conditions such as biological conditions including, but not limited to, vascular complications of type I and type II diabetic induced vasculopathies, other vasculopathies, microangiopathies, renal insufficiency, Alzheimer's syndrome, and inflammation-induced diseases including, but not limited to, atherosclerosis. The compositions may comprise pharmaceutical adjuncts that are needed for administration of the compound or compounds with the desired activity.

The compositions of the present invention may be administered through routes of administration that include, but are not limited to, oral, buccal, nasal, aerosol, topical, transdermal, injectable, slow release, controlled release, iontophoresis, sonophoresis, and other delivery devices and methods. Injectable methods include, but are not limited to, intravenous, intramuscular, intraperitoneal, intraspinal, intrathecal, intracerebroventricular, intraarterial, subcutaneous and intranasal routes.

The compositions for treating the pathologies by the present invention can further include a pharmaceutically

acceptable carrier. The compositions can also include other medicinal agents, pharmaceutical agents, carriers, adjuvants diluents and other pharmaceutical preparations known to those skilled in the art. These agents are known to those skilled in the art and are generally described as being biologically inactive and can be administered to patients without causing deleterious interactions with the active agent. Examples of carriers or excipients for oral administration include corn starch, lactose, magnesium stearate, microcrystalline cellulose and stearic acid, povidone, dibasic calcium phosphate and sodium starch glycolate. Any carrier suitable for the desired administration route is contemplated by the present invention.

It is to be understood that this invention is not limited to the particular formulations, process steps, and materials disclosed herein as such formulations, process steps, and materials may vary somewhat. It is also to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof.

All patents and patent applications disclosed herein are hereby incorporated by reference in their entirety. All references listed or cited herein are incorporated by reference in their entirety.

The foregoing description includes the best presently contemplated mode of carrying out the invention. This description is made for the purpose of illustrating the general principles of the inventions and should not be taken in a limiting sense. This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof, which, after reading the description herein, may suggest themselves to

those skilled in the art without departing from the spirit of the present invention.

### Examples

5

#### **Example 1 AGE-induced Inflammatory Response Determined by IL-6 ELISA:**

Human aortic (HAEC) and microvascular (HMVEC) endothelial cells (Clonetics) were cultured and subcultured according to manufacturer in growth medium (Clonetics): basal medium containing hEGF, hydrocortisone, VEGF, HFGF-B (with heparin), long R3-IGF-1, ascorbic acid, gentamicin/amphotericin and 5% FBS. These cell were allowed to reach >90% confluency before being subjected to experimental treatments. G-HSA was from US Biologicals. Tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) was from R&D Systems.

HMVEC were treated with control medium or medium containing 100 ng/ml TNF $\alpha$  or 300  $\mu$ g/ml G-HSA for 24 hrs. All treatments and controls were carried out in serum free media containing 0.2% albumin. Following treatment, cell media were collected and used for an IL-6 ELISA.

The IL-6 ELISA was carried out using human IL-6 DuoSet ELISA development kit as described by manufacturer (R&D Systems). Mouse anti-human IL-6 was used as the capture antibody (2  $\mu$ g/ml) and biotinylated goat anti-human IL-6 (200 ng/ml) was used as the detection antibody. The culture media were incubated with capture antibody for 2 h at room temperature in 96-well plates. The wells were washed three times with wash buffer (0.05% Tween-20 in phosphate buffered saline (PBS) pH 7.4) followed by incubation with detection antibody for 2 h at room temperature. Following three washes, the wells were incubated with Streptavidin-HRP for 20 min. Color development was read at 450 nm in a microplate reader.

Endothelial cells under basal conditions secreted about 25 - 100 pg / ml, of IL-6. Incubation of endothelial cells with

5 TNF $\alpha$ , a known inducer of IL-6, induced greater than 2-fold increase in IL-6 secretion by endothelial cells. Similarly, G-HSA increased IL-6 secretion by 87%. These data show that G-HSA induced IL-6 secretion in endothelial cells comparable to TNF $\alpha$ . As shown in Figure 1, incubation with TNF $\alpha$  and G-HSA led to an 147% and 87% increase in IL-6 secretion respectively.

10 **Example 2 AGE-induced Inflammatory Response Determined by MCP-1 ELISA:**

HAEC and HMVEC (Clonetics) were cultured and subcultured according to manufacturer in growth medium (Clonetics): basal medium containing hEGF, hydrocortisone, VEGF, HFGF-B (with heparin), long R3-IGF-1, ascorbic acid, gentamicin/amphotericin and 5% FBS. These cells were  
15 allowed to reach >90% confluency before being subjected to experimental treatments. G-HSA was from US Biologicals. TNF $\alpha$  was from R&D Systems.

Cells were treated with control medium or medium  
20 containing 100 ng/ml TNF $\alpha$  or 300  $\mu$ g/ml G-HSA for 24 hrs. All treatments and controls were carried out in serum free media containing 0.2% albumin. Following treatment, media were collected and used for the MCP-1 ELISA.

MCP-1 ELISA was carried out using a DuoSet ELISA  
25 Development System for Human MCP-1 as described by the manufacturer (R&D Systems). 2  $\mu$ g / ml of mouse anti-human MCP-1 was used as the capture antibody and 100 ng / ml biotinylated goat anti-human MCP-1 was used as the detection antibody. The culture media were incubated with capture  
30 antibody for 2 h at room temperature in 96-well plates. The wells were washed three times with wash buffer (0.05% Tween-20 in phosphate buffered saline (PBS) pH 7.4) followed by incubation with detection antibody for 2 h at room temperature. Color development was read at 450 nm in a microplate reader.

The effects of G-HSA on endothelial MCP-1 are shown in Figure 2. Endothelial cells under control conditions produced about 400 pg/ml MCP-1. Incubation with  $\text{TNF}\alpha$  and G-HSA led to 540% and 65% increase in MCP-1 secretion respectively.

5

**Example 3 High-Throughput Screening of Compounds that Block AGE Produced Induction of Inflammatory Response Determined by IL-6 ELISA:**

Endothelial cells were incubated in control media or media containing 300  $\mu\text{g/ml}$  G-HSA or media containing 300  $\mu\text{g/ml}$  G-HSA and 10  $\mu\text{M}$  of a test compound. Representative data for a series of test compounds (A1-A7) from this collection are shown in Figure 3. Compared to untreated cells (74 pg/ml), cells incubated with G-HSA had a two fold increase in IL-6 secretion (150 pg/ml). Of the compounds shown herein, one (A4) was able to block G-HSA induced secretion of IL-6. IL-6 secretion was normalized to near basal levels by compound A4. Although the results in Figure 3 are only for seven compounds, the method of the present invention is designed for high-throughput screening such that greater than 250 compounds can be screened in duplicate by one person in less than one week.

10

15

20

**References:**

25

30

1. Brownlee M, et al. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. *Ann Intern Med* 1984; 101:527-537.
2. Yang CW, et al. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. *Proc Natl. Acad. Sci. U S A.* 1994 91:9436-40.
3. Schmidt AM, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. *Circ Res.* 1999 84:489-97.

4. Yano M, et al. Immunohistochemical localization of glycosylated protein in diabetic rat kidney. *Diabetes Res Clin Pract.* 1990 8:215-9.
5. Cohen MP, et al. Role of Amadori-modified nonenzymatically glycosylated serum proteins in the pathogenesis of diabetic nephropathy. *J Am Soc Nephrol.* 1996 7:183-90.
6. Brownlee M, et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. *Science* 232:1629-1632, 1986.
- 10 7. Li YM, et al. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. *Proc Natl Acad Sci U S A.* 1996 93:3902-7.
8. Piercy V, et al. Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: a study with aminoguanidine in C57/BLKsJ diabetic mice. *Metabolism.* 1998 47:1477-80.
- 15 9. Wautier JL, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. *J Clin Invest.* 1996 97:238-43.
- 20 10. Schmidt AM, et al. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. *J Clin Invest.* 1995 96:1395-403.
- 25 11. Park L, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. *Nat Med.* 1998 4:1025-31.
- 30 12. Hofmann MA, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. *Cell.* 1999 97:889-901.
13. Du Yan S, et al. Amyloid-beta peptide-receptor for advanced glycation end product interaction elicits neuronal expression of macrophage-colony stimulating factor: a
- 35

- proinflammatory pathway in Alzheimer disease. *Proc Natl Acad Sci U S A*. 1997 94:5296-301.
14. Lander HM, et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. *J Biol Chem*. 1997 272:17810-4.
15. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. *Cell Mol Biol. (Noisy-le-grand)*. 1998 44:1013-23.
16. Morohoshi M, et al. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes. *Ann N Y Acad Sci*. 1995 748:562-70.
17. Takagi M, et al. Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. *J Bone Miner Res*. 1997 12:439-46.
18. Wada R, et al. Only limited effects of aminoguanidine treatment on peripheral nerve function, (Na<sup>+</sup>,K<sup>+</sup>)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats. *Diabetologia*. 1999 42:743-7.
19. Soulis T, et al. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. *Kidney Int*. 1996 50:627-34.
20. Laight DW, et al. Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. *Diabetes Metab Res Rev*. 15: 274-82 (1999).
21. Stehouwer CD, et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. *Cardiovasc. Res*. 34:55-68 (1997).
22. Horii Y, et al. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. *Kidney Int Suppl*. 1993 39:S71-5.
23. Huber SA, et al. Interleukin-6 exacerbates early atherosclerosis in mice. *Arterioscler Thromb Vasc Biol*. 1999 19:2364-7.

24. Kado S, et al. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. *Acta Diabetol.* 1999 36:67-72.
- 5 25. Eitner F, et al. Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. *Kidney Int.* 1997 51:69-78.
- 10 26. Saitoh A, Suzuki Y, Takeda M, Kubota K, Itoh K, Tomino Y. Urinary levels of monocyte chemoattractant protein (MCP)-1 and disease activity in patients with IgA nephropathy. *J Clin Lab Anal.* 1998 12:1-5.

## Claims

What is claimed is:

- 5 1. A method for detecting compounds that effect inflammation, comprising,
  - a) adding to cells a composition comprising a compound suspected of effecting inflammation;
  - b) adding a stimulatory agent;
  - 10 c) measuring an amount of at least one determinant of inflammation; and
  - d) comparing the amount of the at least one determinant from c) with an amount of at least one determinant from cells treated with the stimulating agent.
- 15 2. The method of Claim 1, wherein b) adding a stimulatory agent precedes a) the adding of a composition suspected of effecting inflammation to cells.
- 20 3. The method of Claim 1, wherein a) adding a composition comprising a compound suspected of effecting inflammation to cells; and b) adding a stimulatory agent, occur simultaneously.
- 25 4. The method of Claim 1, wherein the compound is a chemical element, molecule, compound, mixture, emulsion, chemotherapeutic agent, pharmacological agent, hormone, antibody, growth factor, cellular factor, nucleic acid, protein, peptide, peptidomimetic, nucleotide, carbohydrate, and combinations, fragments, analogs or derivatives of such entities.
- 30 5. The method of Claim 1, wherein the stimulatory agent is a glycosylated protein.
- 35

6. The method of Claim 5, wherein the glycated protein is G-HSA, or AGE.
- 5 7. The method of Claim 1, wherein the determinant of inflammation comprises a cellular factor selected from the group consisting of NF $\kappa$ -B, IL1- $\beta$ , IL-11, m-CSF, fibrinogen, TNF- $\alpha$ , adhesion molecules, selectins, VCAM-1, CRP, MCP-1 or PAI-1.
- 10 8. A composition, comprising a compound effective for treatment of inflammation, as determined by the method of Claim 1.
- 15 9. The composition of Claim 8 in a pharmaceutically acceptable carrier.
- 20 10. A method for detecting compounds that effect glycated protein accumulation, comprising,  
a) adding to cells a composition comprising a compound suspected of effecting glycated protein accumulation;  
b) adding a stimulatory agent;  
c) measuring an amount of at least one determinant of glycated protein accumulation; and  
25 d) comparing the amount of the at least one determinant from c) with an amount of at least one determinant from cells which have been treated with a glycated protein.
- 30 11. The method of Claim 10, wherein b) adding a stimulatory agent precedes a) the adding of a composition suspected of effecting glycated protein production to cells.

12. The method of Claim 10, wherein a) adding a composition suspected of effecting glycated protein production and b) adding a stimulatory agent occur simultaneously.
- 5
13. The method of Claim 10, wherein the compound is a chemical element, molecule, compound, mixture, emulsion, chemotherapeutic agent, pharmacological agent, hormone, antibody, growth factor, cellular factor, nucleic acid, protein, peptide, peptidomimetic, nucleotide, carbohydrate, and combinations, fragments, analogs or derivatives of such entities.
- 10
14. The method of Claim 10, wherein the stimulatory agent is G-HSA, or AGE.
- 15
15. The method of Claim 10, wherein the determinant of glycated protein accumulation comprises a cellular factor selected from the group consisting of NF $\kappa$ -B, IL1- $\beta$ , IL-11, m-CSF, fibrinogen, TNF- $\alpha$ , adhesion molecules, selectins, VCAM-1, CRP, MCP-1 or PAI-1.
- 20
16. A composition that effects glycated protein accumulation as determined by the method of Claim 10.
- 25
17. The composition of Claim 16 in a pharmaceutically acceptable carrier.
- 30
18. A method for treating inflammation, comprising, administering to a human or animal an effective amount of a composition comprising at least one compound capable of effecting inflammation, wherein the compound is determined by the method of Claim 1.

19. The method of Claim 18, wherein the inflammation is glycated protein inflammation.

5 20. The method of Claim 18, wherein the inflammation is vascular complications of diabetes, ventricular hypertrophy, atherosclerosis, angiopathy, myocarditis, nephritis, arthritis, glomerulonephritis, microangiopathies, renal insufficiency and Alzheimer's disease.

10 21. The method of Claim 18, wherein inflammation is stimulated.

15 22. The method of Claim 18, wherein inflammation is inhibited.

20 23. A method of treating inflammation, comprising administering to a human or animal an effective amount of a composition comprising at least one compound capable of effecting glycated protein accumulation for the treatment of inflammation-induced diseases.

25 24. The method of Claim 23, wherein the inflammation-induced diseases are vascular complications of diabetes, ventricular hypertrophy, atherosclerosis, angiopathy, myocarditis, nephritis, arthritis, glomerulonephritis, microangiopathies, renal insufficiency and Alzheimer's disease.

30

1/3





Figure 1

2/3

**Figure 2**

3/3




Figure 3